Taiclone®
Quality Guarantee

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Venetoclax

Catalog No: tcsc1155

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Specifications

CAS No:
1257044-40-8

Formula:
$C_{45}H_{50}ClN_7O_7S$

Pathway:
Apoptosis

Target:
Bcl-2 Family

Purity / Grade:
>98%

Solubility:
H2O :

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Alternative Names:
GDC-0199;ABT-199

Observed Molecular Weight:
868.44

Product Description

Venetoclax (GDC-0199; ABT-199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with a $\mathbf{K_i}$ of less than 0.01 nM.

IC50 & Target: Ki: 444 nM (Mcl-1)[1]

In Vitro: Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC_{50}=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC_{50}=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC_{50}=3 nM) but is much less effective against BCL-XL-BCL-XS (EC_{50}=2.2 μM) or MCL-1-NOXA complexes[1].

In Vivo: After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI_{max}) of 47% (P[1]. Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days resulted in a significant reduction of leukemic burden (P=0.0048)[2].